8 papers in the library · 44 citations · publishing 2021-2026
July 31, 2026 Samantha Lee Treasure, Alexander de Foe, Sam Gandy et al. preprint
The primary aim of this study is to explore the demographic, experiential, and phenomenological variables of entity encounters during out-of-body experiences (OBEs) through an online survey shared with adults.
Brain and Behavior July 1, 2025 Hugh McGovern, L Bajo, G Hassed et al. 1 citation
The phenomenology of psychedelic experiences has been a long-standing point of interest to researchers. However, internal experience has been relatively relegated, with much work done on the clinical outcomes of psychedelic therapies. Our reflexive thematic analysis revealed that structurally, people on fora write about their experiences sequentially, considering factors prior to (preparatory),...
Psychoactives May 12, 2023 Alexander de Foe 2 citations
Psychedelics have been studied extensively in their broad treatment potential for a variety of mental health disorders. Recently, scholars have turned their attention to the role of psychotherapy in the augmentation, follow-up, and support mechanisms relevant to psychedelic administration. While it is tempting to position psychedelic substances as standalone medicines akin to SSRIs or SNRIs,...
Consciousness and Cognition March 2023 Aidan Mahady, Marcel Takac, Alexander de Foe
A narrative review of autonomous sensory meridian response (ASMR) was carried out. Definitional factors relevant to ASMR were canvassed. Related, but distinctly unique, sensorial phenomena, including frisson, synaesthesia, and misophonia were considered. Finally, the status of literature with respect to clinical outcomes, individual differences, and current research applications was evaluated....
Journal of Psychoactive Drugs October 5, 2022 Annie M. Mccartney, Hugh McGovern, Alexander de Foe 33 citations
Research on the therapeutic potential of psychedelic substances is expanding. A limitation within this field is the unpredictability of individual responses to psychedelics. Better understanding of factors predicting psychedelic experience is essential to clinical progress and wider harm reduction frameworks. Ketamine, MDMA, LSD and psilocybin were selected for comparison due to their promising...
Journal of Psychedelic Studies June 9, 2022 Annie M. Mccartney, Hugh McGovern, Alexander de Foe 8 citations
Abstract Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state...
June 27, 2021 Annie M. Mccartney, Hugh McGovern, Alexander de Foe preprint
Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state of this...
Alvita Sam, Alexander de Foe, Aspasia Stacey Rabba et al. preprint
Background: Autistic adults are under-investigated in psychedelic research, despite speculated elevated likelihood of substance use for therapeutic and recreational purposes.Aims: This study explored contexts of naturalistic psychedelic use and wellbeing and mental health indicators in a group of Autistic adults using psychedelics for therapeutic purposes, and compared these with the broader...